The American Journal of Managed Care3d
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
New bowel cancer test has ‘90% accuracy’ at predicting disease in those at high risk – without invasive procedures
A NEW method for detecting bowel cancer is more than 90 per cent accurate at predicting which higher risk people will develop ...
Pharmabiz7h
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...
gut.bmj6d
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications
Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...
Inflammatory bowel disease tied to higher risk for heart disease
Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a ...
Ibj.com11d
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Science Daily2d
Crohn's Disease News
July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...
2minutemedicine.com3d
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...